Edition:
United Kingdom

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

5.60USD
13 Jul 2018
Change (% chg)

$0.21 (+3.90%)
Prev Close
$5.39
Open
$5.38
Day's High
$5.61
Day's Low
$5.34
Volume
84,680
Avg. Vol
157,254
52-wk High
$9.69
52-wk Low
$4.44

Latest Key Developments (Source: Significant Developments)

Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Astrazeneca Plc ::PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING.  Full Article

Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402.PIERIS PHARMACEUTICAL - THE PHASE 1 STUDY IS BEING DEVELOPED AS PART OF PIERIS' STRATEGIC ALLIANCE WITH ASTRAZENECA.PIERIS PHARMACEUTICALS - DOSING FIRST SUBJECT IN TRIAL FOR PRS-060/AZD1402 BY YEAR END.  Full Article

Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors.Pieris Pharmaceuticals Inc - ‍Geraghty replaces Chau Khuong, who is stepping down from board​.  Full Article

Pieris Pharmaceuticals reports Q3 loss per share $0.16
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update.Q3 loss per share $0.16.Pieris Pharmaceuticals Inc - ‍cash and equivalents totaled $89.9 million as of September 30, 2017, compared to $29.4 million as of December 31, 2016​.  Full Article

Pieris Pharma says entered into a sales agreement with Cowen and Co
Wednesday, 5 Oct 2016 

Pieris Pharmaceuticals Inc : Under agreement co may offer, sell shares of stock, par value $0.001 per share an offering price of up to $35 million through Cowen .Says entered into a sales agreement with Cowen And Company - SEC filing.  Full Article

BRIEF-Pieris Pharmaceuticals Reports Q1 Loss Per Share $0.17

* PIERIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE